NCT05222802 - A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions

Glioblastoma Multiforme

Interventions

DRUG

ERAS-801

Administered orally

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Miami Cancer Institute-Baptist Heath South Florida, Miami

Sarah Cannon Research Institute (Tennessee Oncology), Nashville

Cleveland Clinic Foundation, Cleveland

Henry Ford Health System, Detroit

Huntsman Cancer Institute, Salt Lake City

University of California, Los Angeles, Los Angeles

Dana Farber Cancer Institute, Boston